title: Costs and Cost-Effectiveness of Plasmodium vivax Control.
abstract: The continued success of efforts to reduce the global malaria burden will require sustained funding for interventions specifically targeting Plasmodium vivax The optimal use of limited financial resources necessitates cost and cost-effectiveness analyses of strategies for diagnosing and treating P. vivax and vector control tools. Herein, we review the existing published evidence on the costs and cost-effectiveness of interventions for controlling P. vivax, identifying nine studies focused on diagnosis and treatment and seven studies focused on vector control. Although many of the results from the much more extensive P. falciparum literature can be applied to P. vivax, it is not always possible to extrapolate results from P. falciparum-specific cost-effectiveness analyses. Notably, there is a need for additional studies to evaluate the potential cost-effectiveness of radical cure with primaquine for the prevention of P. vivax relapses with glucose-6-phosphate dehydrogenase testing.
authors.affiliation: MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
authors.forename: Michael T
authors.initials: MT
authors.lastname: White
authors.affiliation: Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors.forename: Shunmay
authors.initials: S
authors.lastname: Yeung
authors.affiliation: Universität Basel, Basel, Switzerland.|Swiss Tropical and Public Health Institute, Basel, Switzerland.|Global Malaria Programme, World Health Organization, Geneva, Switzerland.
authors.forename: Edith
authors.initials: E
authors.lastname: Patouillard
authors.affiliation: Global Malaria Programme, World Health Organization, Geneva, Switzerland.
authors.forename: Richard
authors.initials: R
authors.lastname: Cibulskis
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D009033:Culicidae / Q000469:parasitology; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000517:prevention & control*; D009032:Mosquito Control / Q000191:economics*; D010966:Plasmodium vivax
chemical_list: D000962:Antimalarials